1. Volume 389, Issue 10074, Pages 1103-1113 (March 2017)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial 
Dr György Németh, MD, István Laszlovszky, PharmD, Pál Czobor, PhD, Erzsébet Szalai, MD, Balázs Szatmári, MD, Judit Harsányi, MD, Ágota Barabássy, MD, Marc Debelle, MD, Suresh Durgam, MD, Prof István Bitter, MD, Prof Stephen Marder, MD, Prof W Wolfgang Fleischhacker, MD 
The Lancet 
Volume 389, Issue 10074, Pages (March 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2
Mean change from baseline to week 26 in PANSS-factor score for negative symptoms
p=0·0092 for the overall treatment effect of cariprazine versus risperidone. PANSS-FSNS=Positive and Negative Syndrome Scale factor score for negative symptoms. *p=0·0079. †p=0·0011. ‡p=0·0016. §p=0·0022.
The Lancet  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3 Mean change from baseline to week 26 in PSP total score
p<0·0001 for the overall treatment effect of cariprazine versus risperidone. PSP=Personal and Social Performance Scale. *p=0·0053. †p=0·0046. ‡p=0·0004. §p<0·0001. ¶p<0·0001.
The Lancet  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions